Novartis set to close heart drug study early after strong results

March 31, 2014 6:56 AM

17 0

ZURICH (Reuters) - Swiss drugmaker Novartis is set to end a late-stage clinical trial of a chronic heart failure drug early, following strong interim results.

The Basel-based firm said on Monday an independent committee had unanimously recommended it close its PARADIGM-HF study ahead of time after results showed patients receiving its LCZ696 drug lived longer without being hospitalized for heart failure than those who were given the standard care.

Read more

To category page